Idiopathic Anemia of Aging (IAA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00104169|
Recruitment Status : Terminated (No subject accrual)
First Posted : February 24, 2005
Last Update Posted : August 29, 2008
|Condition or disease||Intervention/treatment||Phase|
|Anemia Aging||Drug: Epoetin Alfa||Phase 2|
As individuals become older, the frequency of anemia increases. While the cause of anemia in many cases can be determined and corrected, in a number of individuals there is no correctable cause found and the patient must live with their anemia. This is known as idiopathic anemia, and can have serious consequences for the individual. Numerous studies have demonstrated that anemia is associated with loss of energy and stamina, causing individuals to decrease their activities, which adversely affects both their sense of well-being as well as their physical strength. Losses in these areas are associated with the clinical manifestations of frailty.
The current pilot study will examine whether or not administration of Epoetin Alfa, a hormone stimulating production of red blood cells, can reverse this type of anemia. We will examine the consequences of reversing the anemia in terms of physical strength and function, cardiovascular function and sense of well-being and mental function.
In this study, individuals with anemia will be treated for six months with Epoetin Alfa following the correction of their anemia and measurements done to evaluate physical strength, performance, cardiac, mental and kidney function. At the end of treatment, individuals will be followed for an additional six months to determine whether the anemia recurs and physical function decreases.
Participation in this study is voluntary. All testing and medication received are free to the participant.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Official Title:||Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA)|
|Study Start Date :||August 2004|
|Actual Primary Completion Date :||May 2007|
|Actual Study Completion Date :||May 2007|
- Response of Anemia
- To determine if there is a beneficial effect of quality of life, cognitive function, and physical function.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00104169
|United States, Maryland|
|Baltimore, Maryland, United States, 21225|
|Principal Investigator:||William Ershler, MD||NIA, NIH|